Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Kamada Anti-SARS-CoV-2

Plasma-derived product · developed by Kamada

Phase 1/2 Most advanced trial (none active)
KMDA Developer
1 Registered trials

What is Kamada Anti-SARS-CoV-2?

Kamada Anti-SARS-CoV-2 is an immune gamma globulin preparation manufactured from convalescent plasma of recovered COVID-19 patients, purified by the developer's proprietary methods. It is studied in COVID-19 and viral pneumonia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Plasma-derived product
Therapy area
Infectious disease
Developer
Kamada, Ltd. (KMDA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04550325 Phase 1/2 Covid19 Completed KMDA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19Pneumonia, Viral

More from Kamada

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KMDA page.

Follow KMDA, the company behind Kamada Anti-SARS-CoV-2

See KMDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KMDA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.